Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?

Are there specific patients where you're more apt to continue versus holding IO while continuing TKI?

Answer from: Medical Oncologist at Academic Institution

I routinely continue anti-PD(L)-1 beyond 2 years while on IO/TKI for patients with clear cell RCC. Of course, this is assuming the patient is tolerating therapy well, continues to be with stable disease/response, and prefers continuation of therapy. I do have a discussion with them at the 2-yea...

Comments

Medical Oncologist at St Louis Cancer Care LLP
My approach is this: if a patient reaches the two-...

Please select the option that best describes you:

Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?

Related Questions